Cite
Kretz AL, von Karstedt S, Hillenbrand A, et al. Should We Keep Walking along the Trail for Pancreatic Cancer Treatment? Revisiting TNF-Related Apoptosis-Inducing Ligand for Anticancer Therapy. Cancers (Basel). 2018;10(3)doi: 10.3390/cancers10030077.
Kretz, A. L., von Karstedt, S., Hillenbrand, A., Henne-Bruns, D., Knippschild, U., Trauzold, A., & Lemke, J. (2018). Should We Keep Walking along the Trail for Pancreatic Cancer Treatment? Revisiting TNF-Related Apoptosis-Inducing Ligand for Anticancer Therapy. Cancers, 10(3), . https://doi.org/10.3390/cancers10030077
Kretz, Anna-Laura, et al. "Should We Keep Walking along the Trail for Pancreatic Cancer Treatment? Revisiting TNF-Related Apoptosis-Inducing Ligand for Anticancer Therapy." Cancers vol. 10,3 (2018). doi: https://doi.org/10.3390/cancers10030077
Kretz AL, von Karstedt S, Hillenbrand A, Henne-Bruns D, Knippschild U, Trauzold A, Lemke J. Should We Keep Walking along the Trail for Pancreatic Cancer Treatment? Revisiting TNF-Related Apoptosis-Inducing Ligand for Anticancer Therapy. Cancers (Basel). 2018 Mar 18;10(3). doi: 10.3390/cancers10030077. PMID: 29562636; PMCID: PMC5876652.
Copy
Download .nbib